Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.058
Neutral
RSI(14)
53.438
Neutral
STOCH(KDJ)(9,3,3)
57.791
Neutral
ATR(14)
0.277
Low Volatility
CCI(14)
25.832
Neutral
Williams %R
44.286
Buy
TRIX(12,20)
0.112
Sell
StochRSI(14)
44.677
Sell
Sonoma Pharmaceuticals Inc
SNOA3.630USD
+0.050+1.40%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
5.99MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Sonoma Pharmaceuticals Inc
Currency: USD Updated: 2025-12-24Key Insights
Sonoma Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 73/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 14.80.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sonoma Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
14.800
Target Price
+322.25%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Sonoma Pharmaceuticals Inc Highlights
StrengthsRisks
Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.
Growing
The company is in a growing phase, with the latest annual income totaling USD 14.29M.
Undervalued
The company’s latest PE is -1.81, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 106.22K shares, increasing 19.12% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 20.87K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.01.
Financial Health
Currency: USD Updated: 2025-12-24The current financial score of Sonoma Pharmaceuticals Inc is 8.45, ranking 64/158 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 5.60M, representing a year-over-year increase of 56.58%, while its net profit experienced a year-over-year increase of 12.46%.
Score
Financials
6.22
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.43
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.61
Sonoma Pharmaceuticals Inc's Company Valuation
Currency: USD Updated: 2025-12-24The current valuation score of Sonoma Pharmaceuticals Inc is 8.19, ranking 25/158 in the Pharmaceuticals industry. Its current P/E ratio is -1.81, which is -94.76% below the recent high of -0.10 and -73.17% above the recent low of -3.14.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 73/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-24The current earnings forecast score of Sonoma Pharmaceuticals Inc is 10.00, ranking 1/158 in the Pharmaceuticals industry. The average price target for Sonoma Pharmaceuticals Inc is 14.80, with a high of 14.80 and a low of 14.80.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
14.800
Target Price
+322.25%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Sonoma Pharmaceuticals Inc
SNOA
1
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-24The current price momentum score of Sonoma Pharmaceuticals Inc is 5.35, ranking 142/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 4.01 and the support level at 3.20, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.618
Buy
MA10
3.573
Buy
MA20
3.490
Buy
MA50
3.612
Buy
MA100
3.931
Sell
MA200
3.528
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-24The current institutional shareholding score of Sonoma Pharmaceuticals Inc is 3.00, ranking 92/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 6.24%, representing a quarter-over-quarter increase of 34.36%. The largest institutional shareholder is The Vanguard, holding a total of 20.87K shares, representing 1.23% of shares outstanding, with 10298.31% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Geode Capital Management, L.L.C.
Thornton (Bruce)
Trombly (Amy Moss)
Dvonch (Jerome J)
Tower Research Capital LLC
Dal (Poggetto John)
1
2
Risk Assessment
Currency: USD Updated: 2025-12-24The current risk assessment score of Sonoma Pharmaceuticals Inc is 2.76, ranking 116/158 in the Pharmaceuticals industry. The company's beta value is 1.62. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.62
VaR
+8.48%
240-Day Maximum Drawdown
+51.30%
240-Day Volatility
+140.10%
Return
Best Daily Return
60 days
+12.97%
120 days
+72.67%
5 years
+72.67%
Worst Daily Return
60 days
-7.76%
120 days
-8.38%
5 years
-49.84%
Sharpe Ratio
60 days
-0.27
120 days
+0.81
5 years
-0.10
Risk Assessment
Maximum Drawdown
240 days
+51.30%
3 years
+93.97%
5 years
+98.97%
Return-to-Drawdown Ratio
240 days
+0.78
3 years
-0.31
5 years
-0.20
Skewness
240 days
+5.51
3 years
+2.97
5 years
+2.80
Volatility
Realised Volatility
240 days
+140.10%
5 years
+147.31%
Standardised True Range
240 days
+7.58%
5 years
+85.44%
Downside Risk-Adjusted Return
120 days
+349.35%
240 days
+349.35%
Maximum Daily Upside Volatility
60 days
+56.46%
Maximum Daily Downside Volatility
60 days
+43.25%
Liquidity
Average Turnover Rate
60 days
+86.25%
120 days
+140.45%
5 years
--
Turnover Deviation
20 days
-0.93%
60 days
-64.79%
120 days
-42.66%
Peer Comparison
Pharmaceuticals
Sonoma Pharmaceuticals Inc
SNOA
6.99 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.78 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Sonoma Pharmaceuticals Inc?
The TradingKey Stock Score provides a comprehensive assessment of Sonoma Pharmaceuticals Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Sonoma Pharmaceuticals Inc’s performance and outlook.
How do we generate the financial health score of Sonoma Pharmaceuticals Inc?
To generate the financial health score of Sonoma Pharmaceuticals Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Sonoma Pharmaceuticals Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Sonoma Pharmaceuticals Inc.
How do we generate the company valuation score of Sonoma Pharmaceuticals Inc?
To generate the company valuation score of Sonoma Pharmaceuticals Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Sonoma Pharmaceuticals Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Sonoma Pharmaceuticals Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Sonoma Pharmaceuticals Inc.
How do we generate the earnings forecast score of Sonoma Pharmaceuticals Inc?
To calculate the earnings forecast score of Sonoma Pharmaceuticals Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Sonoma Pharmaceuticals Inc’s future.
How do we generate the price momentum score of Sonoma Pharmaceuticals Inc?
When generating the price momentum score for Sonoma Pharmaceuticals Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Sonoma Pharmaceuticals Inc’s prices. A higher score indicates a more stable short-term price trend for Sonoma Pharmaceuticals Inc.
How do we generate the institutional confidence score of Sonoma Pharmaceuticals Inc?
To generate the institutional confidence score of Sonoma Pharmaceuticals Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Sonoma Pharmaceuticals Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Sonoma Pharmaceuticals Inc.
How do we generate the risk management score of Sonoma Pharmaceuticals Inc?
To assess the risk management score of Sonoma Pharmaceuticals Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Sonoma Pharmaceuticals Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Sonoma Pharmaceuticals Inc.
